BioWorld8d
New in vitro model of inclusion body myositis based on human iPSC-myotubes
Inclusion body myositis (IBM) is an inflammatory myopathy causing proximal and distal muscle weakness. IBM’s cause remains ...
Physician's Weekly7d
Impact of Placebo on Muscle Strength and Function in Inclusion Body Myositis Trials
The following is a summary of “A systematic review and meta-analysis of the response to placebo in clinical trials of ...
pharmaphorum1mon
Abcuro raises $200m to take muscle disease drug to market
US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of lead drug ulviprubart and file it for approval for inclusion body ...
Yahoo Finance19d
Inclusion Body Myositis Pipeline Market Landscape Report 2025 Featuring Abcuro, Regeneron Pharmaceuticals, and Vandria
Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Inclusion Body Myositis - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. This report offers in-depth insights into ...